Development of a murine mutant ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties

Journal of Immunology

Volumn 160, Issue 5, 1998, Pages 2433-2441

  Bristol, J Andrew ^a   Schlom, Jeffrey ^a   Abrams, Scott I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; H2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P21; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; H2 RESTRICTION; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, CD8; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES; FEMALE; GENES, RAS; H-2 ANTIGENS; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MUTAGENESIS; PEPTIDE FRAGMENTS; RAS PROTEINS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032030669     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Barbacid, M. 1987. Ras genes. Annu. Rev. Biochem. 56:779.
2. Egan, S. E., and R. A. Weinberg. 1993. The pathway to signal achievement. Nature 365:781.
3. Abrams, S. I., P. Horan-Hand, K. Y. Tsang, and J. Schlom. 1996. Mutant ras epitopes as targets for cancer vaccines. Semin. Oncol. 23:1.
4. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
5. Rosenberg, S. A. 1991. Adoptive cellular therapy: clinical applications. In Biologic Therapy of Cancer. V. T. Devita, Jr., S. Hellman, and S. A. Rosenberg, eds. J. B. Lippincott Co., Philadelphia, pp. 214-236.
6. Rothbard, J. B., and M. L. Gefter. 1991. Interactions between immunogenic peptides and MHC proteins. Annu. Rev. Immunol. 9:527.
7. Rock, K. L., L. Rothstein, and B. Benacerraf. 1992. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc. Natl. Acad. Sci. USA 89:8918.
8. + T cell responses. Eur. J. Immunol. 25:435.
9. + T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur. J. Immunol. 25:2588.
10. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
11. Schott, M. E., D. T. Wells, J. Schlom, and S. I. Abrams. 1996. Comparison of linear and branched peplide forms (MAPS) in the induction of helper responses to point-mutated ras immunogens. Cell. Immun. 174:199.
12. Casanova, J. L., P. Romero, C. Widmann, P. Kourilsky, and J. L. Maryanski. 1991. T cell receptor genes in a series of class 1 major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a Plasmodium berghei nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire. J. Exp. Med. 174:1371.
13. Engelhard, V. H. 1994. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 12:181.
14. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102.
15. Lipford, G., S. Bauer, H. Wagner, and K. Heeg. 1995. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine 13:313.
16. Lipford, G., S. Bauer, H. Wagner, and K. Heeg. 1995. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumor antigen, E6. Immunology 84:298.
17. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
18. Naruse, H., K. Ogasawara, K. Takami, K. Kajino, T. Gotohda, Y. Itoh, T. Miyazaki, R. A. Good, and K. Onoe. 1994. Analysis of epitopic residues introduced into the hybrid peptide vaccines prepared according to the cassette theory. Vaccine 12:776.
19. Tourdot, S., M. Oukka, J. C. Manuguerra, V. Magafa, I. Vergnon, N. Riche, M. Bruley-Rosset, P. Cordopatis, and K. Kosmatopoulos. 1997. Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity. J. Immunol. 159:2391.
20. Lehner, P. J., E. C. Y. Wang, P. A. H. Moss, S. Williams, K. Platt, S. M. Friedman, J. I. Bell, and L. K. Borysiewicz. 1995. Human HLA-A201-restricted cytotoxic T lymphocyte recognition of Influenza A is dominated by T cells bearing the Vβ17 gene segment. J. Exp. Med. 181:79.
21. Cochet, M., C. Pannetier, A. Regnault, S. Darche, C. Leclerc, and P. Kourilsky. 1992. Molecular detection and in vivo analysis of the specific T cell response 10 a protein antigen. Eur. J. Immunol. 22:2639.
22. MacDonald, H. R., J. L. Casanova, J. L. Maryanski, and J. C. Cerottini. 1993. Oligoclonal expansion of major histocompatability complex class I-restricted cytolytic T lymphocytes during a primary immune response in vivo: direct monitoring by flow cytometry and polymerase chain reaction. J. Exp. Med. 177:1487.
23. Cole, G. A., T. L. Hogg, and D. L. Woodland. 1994. The MHC class I-restricted T cell response to Sendai virus infection in C57BL/6 mice: a single immuno-dominant epitope elicits an extremely diverse repertoire of T cells. Int. Immunol. 6:1767.
24. Van Elsas, A., H. W. Nijman, C. E. Van Der Minne, J. S. Mourer, W. M. Kast, C. J. M. Melief, and P. I. Schrier. 1995. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21Ras peptide presented by HLA-A*0201. Int. J. Cancer 61:389.
25. 13 →ASP), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol. Immunother. 40:165.
26. + T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell. Immunol. In press.